Related Articles for PubMed (Select 18570663)

Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.

Espíndola MB, Corleta OC.

World J Surg Oncol. 2008 Jun 20;6:65.

PMID: 18570663 [PubMed - indexed for MEDLINE]

Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma.

Sviatoha V, Rundgren A, Tani E, Hansson J, Kleina R, Skoog L.

Cytopathology. 2002 Feb;13(1):11-21.

PMID: 11985564 [PubMed - indexed for MEDLINE]

Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.

Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P.

Mod Pathol. 2007 Apr;20(4):416-26.

PMID: 17384650 [PubMed - indexed for MEDLINE]

Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.

Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, Bottoni U, Innocenzi D, Calvieri S, Scuderi N, Frati L, Aglianò AM.

J Clin Oncol. 2003 Jan 15;21(2):306-12.

PMID: 12525523 [PubMed - indexed for MEDLINE]

Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response.

Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Collan Y, Pyrhönen S.

Oncology. 2002;62(3):259-68.

PMID: 12065874 [PubMed - indexed for MEDLINE]

Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.

Prenzel KL, Baldus SE, Mönig SP, Tack D, Sinning JM, Gutschow CA, Grass G, Schneider PM, Dienes HP, Hölscher AH.

Cancer. 2004 May 1;100(9):1909-17.

PMID: 15112272 [PubMed - indexed for MEDLINE]

Molecular oncogene markers and their significance in cutaneous malignant melanoma.

Konstadoulakis MM, Vezeridis M, Hatziyianni E, Karakousis CP, Cole B, Bland KI, Wanebo HJ.

Ann Surg Oncol. 1998 Apr-May;5(3):253-60.

PMID: 9607628 [PubMed - indexed for MEDLINE]

Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis.

Spanknebel K, Coit DG, Bieligk SC, Gonen M, Rosai J, Klimstra DS.

Am J Surg Pathol. 2005 Mar;29(3):305-17.

PMID: 15725798 [PubMed - indexed for MEDLINE]

Adjuvant irradiation for axillary metastases from malignant melanoma.

Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MI.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):964-72.

PMID: 11958890 [PubMed - indexed for MEDLINE]

10:

Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.

Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, Ashfaq R.

Cancer. 2003 Dec 15;98(12):2554-9.

PMID: 14669273 [PubMed - indexed for MEDLINE]

11:

Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma.

Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J, Pyrhönen S.

Melanoma Res. 2004 Feb;14(1):29-37.

PMID: 15091191 [PubMed - indexed for MEDLINE]

12:

Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand.

Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Screaton G, Hersey P.

Hum Pathol. 2006 Oct;37(10):1286-94. Epub 2006 Jul 18.

PMID: 16949935 [PubMed - indexed for MEDLINE]

13:

HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes.

Kalogeraki A, Garbagnati F, Darivianaki K, Delides GS, Santinami M, Stathopoulos EN, Zoras O.

Anticancer Res. 2006 Sep-Oct;26(5A):3551-4.

PMID: 17094481 [PubMed - indexed for MEDLINE]

14:

CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.

Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A.

J Clin Pathol. 2007 Jun;60(6):596-9. Epub 2006 Mar 7.

PMID: 16522748 [PubMed - indexed for MEDLINE]

15:

Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings.

Tchernev G, Orfanos CE.

J Cutan Pathol. 2007 Mar;34(3):247-56.

PMID: 17302609 [PubMed - indexed for MEDLINE]

16:

Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.

Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS, Jung SH, Wenck S, Coleman JJ 3rd.

Plast Reconstr Surg. 2003 Aug;112(2):486-97.

PMID: 12900606 [PubMed - indexed for MEDLINE]

17:

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.

D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL.

Breast Cancer Res Treat. 2007 Mar;101(3):279-84. Epub 2006 Jul 12.

PMID: 16835704 [PubMed - indexed for MEDLINE]

18:

Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer.

Sierra A, Castellsagué X, Tórtola S, Escobedo A, Lloveras B, Peinado MA, Moreno A, Fabra A.

Clin Cancer Res. 1996 Nov;2(11):1887-94.

PMID: 9816145 [PubMed - indexed for MEDLINE]

19:

The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.

Koda M, Sulkowska M, Kanczuga-Koda L, Tomaszewski J, Kucharczuk W, Lesniewicz T, Cymek S, Sulkowski S.

Oncol Rep. 2007 Jul;18(1):113-9.

PMID: 17549355 [PubMed - indexed for MEDLINE]

20:

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

PMID: 17430582 [PubMed - indexed for MEDLINE]

Recent Activity